Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GW Pharmaceuticals Plc receives orphan drug designation by FDA for epidiolex in the treatment of Lennox-Gastaut Syndrome


Friday, 28 Feb 2014 08:00am EST 

GW Pharmaceuticals Plc:Says that the U.S. Food and Drug Administration has granted orphan drug designation for Epidiolex, GW's product candidate that contains plant-derived Cannabidiol as its active ingredient, for use in treating children with Lennox-Gastaut syndrome, a rare and severe form of childhood-onset epilepsy.Epidiolex is an oral liquid formulation of a highly purified extract of CBD, a non-psychoactive molecule from the cannabis plant. 

Company Quote

429.0
7.0 +1.66%
27 Nov 2014